Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Seaport Therapeutics now has a fresh buy rating from Canaccord Genuity, filed this morning, arriving into a stock that has fallen another 7% this week and 31% over the past month, with the borrow market still essentially locked.
The most notable development since the last note is the Canaccord initiation. Analyst Sumant Kulkarni started coverage today with a Buy and a $28 target, the lowest price target among covering analysts, but still 74% above the current $16.08 close. That wide gap between where the stock trades and where the Street thinks it is worth reflects the binary nature of the thesis. Raymond James initiated Strong Buy at $46 in late September, HC Wainwright holds a $50 target with repeated Buy reiterations, and Leerink and Citigroup both came in at $35 earlier in the year. Every analyst on the register carries a bullish rating. The consensus mean target is $37, more than double the current price. The Street is uniformly constructive; the market is not.
The borrow market has tightened again after a brief loosening. Availability slipped to 0.07% on Monday before recovering to 3.8% on Tuesday, still extremely tight. For context, the 52-week low was 0.05%. Lenders are not releasing stock. Cost to borrow has climbed to 8%, up 6% on the week and 32% over the past month, a sustained drift higher that reflects ongoing demand to hold short positions rather than a single spike. The ORTEX short score is 87.6, essentially unchanged from the 87.8 to 88.2 range that has persisted for the past two weeks, placing Seaport in the top decile of short conviction across the universe. Short interest in share terms ticked up fractionally on the day but is down about 5% on the week, a small reduction that has not materially altered the picture. The borrow picture is one of a lending pool that remains close to fully committed, with shorts paying a rising rate to hold their positions.
The bull and bear cases are well defined. Bulls point to the Glyph platform's demonstrated pharmacokinetic advantages: GlyphAllo showed more than 9x higher oral exposure versus its native compound, and recent Phase 1 driving-simulation data showed no next-morning impairment, removing one key anxiety around the program. Peak sales estimates for GlyphAllo alone run to roughly $7 billion, with gross margins expected above 95% given the small-molecule profile. Bears counter that the company has no operating history, that BUOY-1 top-line data is not due until the first half of 2027, and that the broader psychiatric drug approval track record is thin. Only two anxiety medicines were approved in the US from 2008 to 2024. The price-to-book multiple has compressed to 2.4x, down nearly a full turn over the past month, as the stock's slide has begun to eat into the valuation cushion that cash and book value provided.
The ownership structure is worth noting because it shapes the float dynamics. PureTech Health holds 31% of shares. ARCH Venture Fund XII filed a Schedule 13D in May at 11.9%, and General Atlantic filed its own 13D at 11.5% the same week. Those two filings carry activist-intent designations, meaning they disclosed intent beyond passive holding. Together with PureTech, roughly 55% of the company sits with three committed sponsors. As always, 13D/G positions are as-last-disclosed around the 5% threshold, and a holder who drops below that level may not file again. Retail attention has also spiked sharply: Wikipedia page views registered a z-score of 5.6 against the prior 90 days, the highest reading in the dataset, suggesting a meaningful uptick in individual investor interest around the time of the recent sell-off.
Earnings on November 3 are now 20 days away. The next print is unlikely to contain revenue, so the session will turn almost entirely on pipeline commentary and any update to the BUOY-1 timeline. Given three prior earnings reactions of minus 1%, plus 5%, and plus 7% in one day, the historical pattern shows moves can be sharp in either direction, with the outcome driven by clinical news rather than financial results. The combination of near-zero borrow availability, a rising cost to maintain short positions, and a Street that initiated a new buy this morning at nearly double the current price means the next significant data point will determine which of those two camps had the story right.
See the live data behind this article on ORTEX.
Open SPTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
